Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
Predictive Oncology Inc. (AIPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023. Q2 2023 and Recent Highlights: Initiated PEDAL-Cancer Research Horizons collabor..." |
|
| 05/15/2023 |
8-K
| Quarterly results|
Docs:
|
"Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three months ended March 31, 2023, and provided a corporate update. The company reported a net loss of $3.4 million on total net revenue of $0.2 million for the first quarter 2023. Q1 2023 and Recent Highlights: Announced groundbreaking partnership with Cancer Research Ho..." |
|
| 11/10/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"Predictive Oncology Reports Third Quarter Financial Results EAGAN, Minn., Nov. 10, 2021 -- Results from the third quarter show strong potential for future growth, said Predictive Oncology today, announcing financial results for the quarter ended September 30, 2021. All three of Predictive Oncology’s reportable segments recognized revenue for the quarter, and the loss per common share was reduced to $0.08, compared to $0.46 for the same period in 2020. The knowledge-driven company, which is applying artificial intelligence to personalized medicine and drug discovery, also provided an update on its business activities. Highlights from the quarter include: “We are looking forward to the outcome of our Discovery 21 program, which we believe will realize our goal of providing pharmaceutical com..." |
|
| 11/16/2020 |
8-K
| Quarterly results|
Docs:
|
"-- Tables Follow – PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS Current Assets: Cash $ 2,474,312 $ 150,831 Accounts Receivable 508,265 297,055 Inventories 205,908 190,156 Prepaid Expense and Other Assets 269,282 160,222 Total Current Assets 3,457,767 798,264 Fixed Assets, net 3,755,464 1,507,799 Intangibles, net 3,464,327 3,649,412 Lease Right-of-Use Assets 1,790,130 729,745 Goodwill 12,693,290 15,690,290 Total Assets $ 25,160,978 $ 22,375,510 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 1,628,944 $ 3,155,641 Notes Payable – Net of Discounts of $495,100 and $350,426 5,751,876 4,795,800 Accrued Expenses 2,530,385 2,371,633 Derivative Liability 1,052,494 50,989 Deferred Revenue 66,123 40,384 Lease Liability 577,505 459,481 Total Curre..." |
|
| 08/13/2020 |
8-K
| Quarterly results |
| 06/08/2020 |
8-K
| Quarterly results|
Docs:
|
"-- Tables Follow – Predictive Oncology, Inc. Consolidated Balance Sheets ASSETS Current Assets: Cash and Cash Equivalents $ 3,056,243 $ 150,831 Accounts Receivable 269,777 297,055 Inventories 155,683 190,156 Prepaid Expense and Other Assets 262,470 160,222 Total Current Assets 3,744,173 798,264 Fixed Assets, net 1,377,724 1,507,799 Intangibles, net 3,605,417 3,649,412 Lease Right-of-Use Assets 631,392 729,745 Goodwill 15,690,290 15,690,290 Total Assets $ 25,048,996 $ 22,375,510 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 3,128,520 $ 3,155,641 Notes Payable – Net of Discounts of $493,490 and $350,426 3,817,176 4,795,800 Accrued Expenses 2,142,591 2,371,633 Derivative Liability 2,814,798 50,989 Deferred Revenue 44,129 40,384 Lease Liability – Net of Long-ter..." |
|
| 11/15/2019 |
8-K
| Quarterly results |
| 08/19/2019 |
8-K
| Quarterly results |
| 05/15/2019 |
8-K
| Quarterly results|
Docs:
|
"March 31, 2019 December 31, 2018 ASSETS Current Assets: Cash and Cash Equivalents $ 1,124,730 $ 162,152 Accounts Receivable 173,443 232,602 Notes Receivable 1,801,479 497,276 Inventories 289,023 241,066 Prepaid Expense and other assets 265,584 318,431 Total Current Assets 3,654,259 1,451,527 Notes Receivable - 1,112,524 Fixed Assets, net 148,709 180,453 Intangibles, net 950,049 964,495 Lease Right-of-Use Assets 333,944 - Total Assets $ 5,086,961 $ 3,708,999 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 432,198 $ 445,689 Note Payable – Bridge Loan Net of Discount of $646,524 and $969,786 1,812,037 1,327,942 Notes Payable – Net of Discount of $352,961 and $63,028 1,267,039 306,972 Accrued Expenses 797,599 1,279,114 Derivative Liability 353,210 272,745 Deferred ..." |
|
| 11/14/2018 |
8-K
| Quarterly results, Conference call transcript |
| 08/14/2017 |
8-K
| Quarterly results |
| 05/15/2017 |
8-K
| Form 8-K - Current report |
| 11/15/2016 |
8-K
| Form 8-K - Current report |
| 05/23/2016 |
8-K
| Quarterly results |
| 03/17/2016 |
8-K
| Quarterly results|
Docs:
|
"Skyline Announces Fourth Quarter and Year End 2015 Results MINNEAPOLIS, March 17, 2016 -- Skyline Medical Inc. , producer of the FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal, today reported its financial results for the three months and year ended December 31, 2015. Josh Kornberg, CEO of Skyline, commented, “The overwhelmingly positive response to the STREAMWAY System by surgeons, nurses and hospital administrators continues to be a testament to the quality of our products and the need for such a solution in the market. We quickly resumed direct sales activities and expanded our reach across the U.S. since completing a capital raise in August 2015 concurrent with an uplisting to the NASDAQ Capital Market. As a result, we rounded out the year with 20 c..." |
|
| 05/21/2013 |
8-K
| Quarterly results |
|
|